Drug Profile
Research programme: TDP1 and TOP1 inhibitors - Aphios/National Cancer Institute
Alternative Names: APH 0804; Tdp-1 inhibitors; Tyrosyl-DNA phosphodiesterase 1 protein inhibitorsLatest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Aphios Corporation; National Cancer Institute (USA)
- Class
- Mechanism of Action DNA topoisomerase I inhibitors; TDP1 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for research development in Cancer in USA
- 06 Jan 2015 Early research is ongoing in USA
- 01 Apr 2009 Early research in Cancer in USA (unspecified route)